Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2

Status

Recruiting 3Completed 3

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Breast 2

Conditions

Pancreatic Neoplasms 53Carcinoma, Non-Small-Cell Lung 36Urinary Bladder Neoplasms 31Neoplasm Metastasis 20Lung Neoplasms 20Ovarian Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Triple Negative Breast Neoplasms 14Neoplasms 14Nasopharyngeal Carcinoma 14Biliary Tract Neoplasms 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Breast Neoplasms 12Fallopian Tube Neoplasms 10Recurrence 9Gallbladder Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Bile Duct Neoplasms 7Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Uterine Cervical Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5Hodgkin Disease 5Endometrial Neoplasms 5Osteosarcoma 4Melanoma 4Gastrointestinal Neoplasms 4

Interventions

pembrolizumab 52Paclitaxel 19Carboplatin 15Cisplatin 13lenvatinib 10Docetaxel 8Saline Solution 7Capecitabine 7Pemetrexed 6Oxaliplatin 6Gemcitabine 6Fluorouracil 6olaparib 5Leucovorin 5Albumin-Bound Paclitaxel 5belzutifan 4Bevacizumab 4130-nm albumin-bound paclitaxel 4patritumab deruxtecan 3Glucose 3Acetaminophen 3liposomal doxorubicin 2Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Doxorubicin 2Dexamethasone 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Gemcitabine × 90 days × Clear all
NCT06788912 2026-05-26

MK-3475-01E

Merck Sharp & Dohme LLC

Phase 2 Recruiting
60 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06841354 2026-05-22

TroFuse-011

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,000 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06623422 2026-05-15

INTerpath-009

Merck Sharp & Dohme LLC

Phase 3 Recruiting
680 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04924062 2026-04-15

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
158 enrolled 19 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Merck Sharp & Dohme LLC

Phase 3 Completed
1,069 enrolled 19 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04191135 2026-03-03

KEYLYNK-009

Merck Sharp & Dohme LLC

Phase 2 Completed
462 enrolled 30 charts
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡